Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance

Sexually Transmitted Diseases
Gerard J B SonderAnneke van den Hoek

Abstract

To compare 2 regimens for HIV postexposure prophylaxis (PEP) as to safety, adherence, outcome, and follow-up in men who have sex with men (MSM) in Amsterdam. Since 2000, all MSM starting HIV PEP in Amsterdam have been followed in 1 location. The regimen was comprised of zidovudine or lamivudine and nelfinavir (regimen 1) until 2005, when nelfinavir was replaced by atazanavir (regimen 2). All patient data, including data on PEP side effects and testing for alanine aminotransferase (ALT), were systematically recorded and compared between the 2 regimens from 2000 to 2007. HIV PEP was prescribed 309 times to MSM. Of the 261 who were followed up, 237 (91%) completed their 28-day course. Although fewer patients had diarrhea on regimen 2 than on regimen 1 (P = 0.00), the proportion completing either course was the same: 98 of 110 (89%) and 139 of 151 (92%), respectively (P = 0.42). Only 1 patient with severely elevated ALT was advised to stop PEP, he also had serious illness. MSM at least 30 years of age and MSM who had sex with a partner known to be HIV-positive completed their course significantly more often than those under 30 and those who had sex with a partner of unknown HIV status (P < 0.005). Of MSM who completed PEP, 5 seroco...Continue Reading

References

Mar 17, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mauro SchechterUNKNOWN Praca Onze Study Team
Mar 25, 2005·Sexually Transmitted Diseases·Márcia Teixeira GarciaPriscila Maria O Papaiordanou
Jul 5, 2005·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Judith A LindenColleen LaBelle
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michelle E RolandJeffrey N Martin
Sep 19, 2006·Sexually Transmitted Diseases·Gerard J B SonderRoel A Coutinho
Jan 2, 2007·Current Opinion in Infectious Diseases·Michelle E Roland
Apr 18, 2007·Annals of Internal Medicine·Myron S CohenLynn Paxton
Jul 16, 2008·Antiviral Research·Lauren E Yauch, Sujan Shresta
Aug 8, 2008·Sexually Transmitted Diseases·Gini G C Van RijckevorselAnneke Van Den Hoek
Jun 1, 2004·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·J Almeda On Behalf Of The Euro-Nonopep Project Group

❮ Previous
Next ❯

Citations

Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michelle E RolandJeffrey N Martin
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Jan 4, 2013·American Journal of Preventive Medicine·Stephanie E CohenSusan Philip
May 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nathan FordKenneth H Mayer
May 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nathan FordZara Shubber
Dec 3, 2015·Revista brasileira de epidemiologia = Brazilian journal of epidemiology·Ivia MaksudSandra Lucia Filgueiras
Jul 26, 2018·Journal of the International AIDS Society·Françoise Barré-SinoussiPeter Godfrey-Faussett
Dec 1, 2018·BMJ : British Medical Journal·Mark J SiednerIsaac I Bogoch
Jun 29, 2013·AIDS·Julie E MyersBernard M Branson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.